In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PETNET Solutions Inc.

Division of Siemens Healthineers AG/Siemens Medical Solutions USA Inc.

Latest From PETNET Solutions Inc.

Deals Shaping The Medical Industry (12/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Healthy Convergence

Some health care firms have managed to work around the industry's well-documented growth constraints by pursuing a strategy of convergence--finding new combinations of formerly distinct market segments for pharmaceuticals, devices, and diagnostics. The authors, at Bain & Company, outline the considerations that drive the evaluation of and set the stage for convergence opportunities. Companies can use them to capitalize on an array of opportunities throughout the commercialization continuum and develop a response to potential threats from the outside.
BioPharmaceutical Medical Device

How Experimental Medicine Is Affecting Big Pharma

Big Pharma is rethinking the clinical trials process, establishing tighter links between clinical R&D and discovery. The buzzword is experimental medicine--a catchall for the set of tools and clinical strategies used to determine whether hitting a drug target modulates a disease process in a therapeutically useful way. By so doing, companies hope to reign in clinical costs--the bulk of drug development expenses--by avoiding massive drilling into what prove to be dry drug development holes. To some, experimental medicine is also a process to create a bridge between discovery research and clinical R&D--a large task given that they hold different mindsets.
BioPharmaceutical Strategy

Imaging in its Heyday: Clinical Applications (Part II)

As scientific innovation in molecular imaging explodes, experts believe the big payoff will be in clinical, rather than research, applications. But absent validating clinical data, businesses remain hesitant to jump into the field.
Medical Device Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • PET Net Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Siemens Healthineers AG
  • Senior Management
  • Contact Info
  • PETNET Solutions Inc.
    Phone: (865) 675-4400
    810 Innovation Dr.
    Knoxville, TN 37932-2571